By species

The patient first. The chemistry second.

Pick a species — we'll surface the peptides studied for it, the honest caveats, and a representative case.

🐕

Body-weight–based dosing; comorbid endocrine disease common in seniors — screen first.

🐈

More than 50% of domestic cats are overweight/obese — and weight reduction is among the few interventions shown to extend feline lifespan.

🐎

Many peptides are banned in racing/competition (e.g., TB-500). Verify with the governing body before any clinical use.

🐇

Data is thinnest here. Veterinary judgment and extrapolation are essential; we flag every monograph where species-data is absent.

🎗️

Coordinate with primary oncology team. Investigational peptides are adjuncts — never replacements for standard of care.

🦮

Handler-driven protocols; document rest & return-to-work criteria alongside peptide plans.